개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.10
- 수록면
- 261 - 266 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Sirolimus has potent anti-rejection activity as well as the ability to prolong allograft survival and reduce nephrotoxicity. This study was designed to evaluate the efficacy and safety of sirolimus in Korean de novo renal transplantation.
Methods: We included 79 patients who received sirolimus at nine Korean transplantation centers in the intention-to-treat and valid-for-safety analyses. The study was an open, single treatment arm multicenter trial with 12 months of patient follow-up. Initially, patients received 2 ㎎ of sirolimus (after 6 ㎎ of loading does) with cyclosporine and steroids. Sirolimus was administered for up to 12 months. Antibody induction was not used. At 3 months after transplantation, cyclosporine was progressively withdrawn over 4 to 8 weeks while sirolimus was adjusted to obtain trough concentrations within 15∼30 ng/㎖ up to 6 months and concentrations within 12∼24 ng/㎖ between 7 and 12 months.
Results: The proportion of patients who completed the 12-month sirolimus medication per protocol was 74.7% (59/79). Cyclosporine withdrawal was possible in 64 recipients (81.0%). Fifteen patients discontinued sirolimus before cyclosporine withdrawal, and 5 recipients did so after successful cyclosporine withdrawal. Most common causes of sirolimus discontinuation were graft rejection (n=8). Incidence of biopsy-proven acute rejection within 6 months after transplantation was 15.2%. Patient and graft survival rates at 12 months post transplantation were 97.5% and 96.2%, respectively. During the study period, three graft losses occurred by patient death.
Conclusion: Based on this study, cyclosporine and sirolimus induction followed by cyclosporine withdrawal at 3 months post-transplant is considered to be efficient and safe after primary renal transplantation.
Methods: We included 79 patients who received sirolimus at nine Korean transplantation centers in the intention-to-treat and valid-for-safety analyses. The study was an open, single treatment arm multicenter trial with 12 months of patient follow-up. Initially, patients received 2 ㎎ of sirolimus (after 6 ㎎ of loading does) with cyclosporine and steroids. Sirolimus was administered for up to 12 months. Antibody induction was not used. At 3 months after transplantation, cyclosporine was progressively withdrawn over 4 to 8 weeks while sirolimus was adjusted to obtain trough concentrations within 15∼30 ng/㎖ up to 6 months and concentrations within 12∼24 ng/㎖ between 7 and 12 months.
Results: The proportion of patients who completed the 12-month sirolimus medication per protocol was 74.7% (59/79). Cyclosporine withdrawal was possible in 64 recipients (81.0%). Fifteen patients discontinued sirolimus before cyclosporine withdrawal, and 5 recipients did so after successful cyclosporine withdrawal. Most common causes of sirolimus discontinuation were graft rejection (n=8). Incidence of biopsy-proven acute rejection within 6 months after transplantation was 15.2%. Patient and graft survival rates at 12 months post transplantation were 97.5% and 96.2%, respectively. During the study period, three graft losses occurred by patient death.
Conclusion: Based on this study, cyclosporine and sirolimus induction followed by cyclosporine withdrawal at 3 months post-transplant is considered to be efficient and safe after primary renal transplantation.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
신장이식 환자에서 Cyclosporine의 적정 투여량
Annals of Surgical Treatment and Research
1994 .08
-
스테로이드 저항성 신증후군에서 cyclosporine 치료 반응 및 결과
Clinical and Experimental Pediatrics
2008 .01
-
Cyclosporine Toxicity of the Renal Allograft
대한외과학회 학술대회 초록집
2001 .11
-
신장이식 환자에서 전혈중 Cyclosporine 농도의 측정 : 특이성 및 비특이성 항체를 이용한 방사면역측정법의 비교
Annals of Surgical Treatment and Research
1991 .10
-
조혈모세포 이식을 받은 소아 환자에서 cyclosporine의 집단 약동학 분석
한국임상약학회지
2018 .01
-
한국인 신장이식후 Cyclosporine 전혈중 농도에 관한 고찰
Annals of Surgical Treatment and Research
1986 .01
-
흰쥐 동종 이식 심장에 대한 Cyclosporine A 연속 정맥 투여의 효과
Annals of Surgical Treatment and Research
1990 .07
-
Sirolimus 사용 후 사구체 기저막 세극막 관련 분자의 변화
Childhood Kidney Diseases
2010 .01
-
소아 신증후군에서의 Cyclosporine의 치료 효과 및 안전성
한국임상약학회지
2004 .01
-
신장이식 환자에서 발생한 시롤리무스에 의한 폐렴
대한내과학회지
2010 .01
-
A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata
Annals of Dermatology
2016 .01
-
The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
Korean Journal of Ophthalmology
2013 .01
-
구강 편평태선 환자에서 steroid와 cyclosporine의 국소 도포 효과
대한구강악안면외과학회지
2004 .01
-
Cyclosporine을 사용한 생체신 이식에서 이식전 공여자 특이 수혈의 효과
Annals of Surgical Treatment and Research
1989 .01
-
신이식의 합병증에 관한 임상연구
Annals of Surgical Treatment and Research
1992 .11
-
Clinical Outcomes of Cyclosporine Treatment for Noninfectious Uveitis
Korean Journal of Ophthalmology
2012 .01
-
사이클로스포린 신경독성에 의한 가역성 뇌관류 저하 : 증례보고
대한핵의학회지
2000 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0